Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.58 USD | -0.36% | +18.85% | +28.87% |
Financials (USD)
Sales 2024 * | 231M | Sales 2025 * | 233M | Capitalization | 269M |
---|---|---|---|---|---|
Net income 2024 * | 13M | Net income 2025 * | 14M | EV / Sales 2024 * | 1.17 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.16 x |
P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
33
x | Employees | 185 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.88% |
Latest transcript on Puma Biotechnology, Inc.
1 day | -0.36% | ||
1 week | +18.85% | ||
Current month | -10.29% | ||
1 month | -13.62% | ||
3 months | +28.57% | ||
6 months | +108.21% | ||
Current year | +28.87% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Auerbach
CEO | Chief Executive Officer | 54 | 10-09-14 |
Maximo Nougues
DFI | Director of Finance/CFO | 55 | 18-11-04 |
Alvin Wong
CTO | Chief Tech/Sci/R&D Officer | 71 | 13-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Miller
BRD | Director/Board Member | 67 | 18-02-22 |
Jay Moyes
BRD | Director/Board Member | 70 | 12-04-26 |
Alan Auerbach
CEO | Chief Executive Officer | 54 | 10-09-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 5.58 | -0.36% | 357,785 |
24-03-26 | 5.6 | +0.18% | 528,485 |
24-03-25 | 5.59 | +4.88% | 738,420 |
24-03-22 | 5.33 | -0.37% | 924,299 |
24-03-21 | 5.35 | +13.95% | 1,167,505 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.87% | 269M | |
+9.16% | 45.97B | |
+54.09% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |